H

Halozyme Therapeutics
D

HALO

58.230
USD
-0.54
(-0.92%)
مغلق
حجم التداول
32,491
الربح لكل سهم
5
العائد الربحي
-
P/E
15
حجم السوق
7,175,158,830
أصول ذات صلة
ALNY
ALNY
1.29
(0.39%)
329.01 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
N
NTLA
0.830
(6.50%)
13.595 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
V
VCEL
0.410
(1.03%)
40.160 USD
المزيد
الأخبار المقالات

العنوان: Halozyme Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.